tbuckley/cabot-search huggingface dataset:
847P Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study
Authors: S. Leyvraz, M. Schütte, T. Kessler, M. Lamping, S. Burock, S. Ochsenreither, V. Amstislavskiy, T. Risch, I. Jelas, C. Ulrich, G. Dobos, F. Klauschen, R. Schäfer, B. Lange, K. Klinghammer, M-L. Yaspo, U. Keilholz
Journal: Annals of Oncology (2022)
1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis
Authors: S. Lau, M. Makarem, M. Cabanero, M-S. Tsao, P. Bradbury, F.A. Shepherd, G. Liu, N. Leighl, A. Sacher
Journal: Annals of Oncology (2022)
389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
Authors: Y. Kito, K. Yamazaki, H. Shoji, T. Yamada, T. Tsushima, S. Mitani, K. Shiraishi, H. Yasui, H. Hara, K. Shimozaki, T. Esaki, H. Shimokawa, S. Kajiura, T. Masuishi, E. Baba, K. Yoshimura, H. Kawakami, S. Hironaka, K. Muro
Journal: Annals of Oncology (2022)
370P Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial
Authors: A. Sartore Bianchi, S. Lonardi, A. Amatu, F. Bergamo, G. Mauri, C. Martino, K. Bencardino, M.D. Rizzato, F.M. Tosi, S. Ghezzi, A. Sapino, A. Bardelli, L. Trusolino, S. Marsoni, S. Siena
Journal: Annals of Oncology (2022)
108P Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition
Authors: A.A. Davis, J. Luo, T. Zheng, C. Dai, R. Suresh, F.O. Ademuyiwa, C. Rigden, K. Clifton, K. Weilbaecher, A.E. Frith, P. Tandra, T. Summa, S. Thomas, L. Peterson, X. Wang, P. Du, S. Jia, B.L. King, J. Krishnamurthy, C.X. Ma
Journal: Annals of Oncology (2022)
367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study
Authors: M.M. Germani, D. Rossini, G. Vetere, M. Giordano, I. Capone, P. Manca, F. Bergamo, V. Conca, B. Borelli, A. Boccaccino, M. Angelini, F. Simionato, N. Pella, C. Morelli, G. Zucchelli, C. Cremolini
Journal: Annals of Oncology (2022)
176P The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related lymphoedema: Secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10
Authors: S. Nakamoto, N. Taira, K. Kawada, D. Takabatake, Y. Miyoshi, S. Kubo, Y. Suzuki, M. Yamamoto, Y. Ogasawara, S. Yoshitomi, K. Hara, T. Shien, T. Iwamoto, S. Ohsumi, M. Ikeda, Y. Mizota, S. Yamamoto, H. Doihara
Journal: Annals of Oncology (2022)
860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
Authors: K. de Joode, K.P.M. Suijkerbuijk, J.W.B. de Groot, A.A.M. Van der Veldt, H.M. Westgeest, R. de Wijn, D.P. Hurkmans, D.M.A. van den Heuvel, K. Schmidt, T. van Doorn, H.M. Pinedo, J.P. Groten, E.M.E. Verdegaal, S.H. van der Burg, J.G. Aerts, R. Debets, E. Kapiteijn, R.H. Mathijssen
Journal: Annals of Oncology (2022)
705TiP Phase II trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck
Authors: C. Le Tourneau, L.F. Licitra, N. Bourayou, R. Schaub, M. Bartenstein, W. Wei, E.E.W. Cohen
Journal: Annals of Oncology (2022)
648TiP Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study
Authors: A. de la Fuente Burguera, F.J. Peñalver Parraga, R. Cordoba Mascunano, P. Herrera, M.T. Olave, C. Martiniez Chamorro, I. Jarque, M. Estevez Fernandez
Journal: Annals of Oncology (2022)
835P Efficacy of checkpoint inhibitors and targeted therapy depending on the line of treatment in patients with advanced / metastatic melanoma
Authors: B. Cybulska-Stopa, A.M. Czarnecka, K. Ostaszewski, K. Piejko, M. Ziętek, R. Dziura, L. Galus, B.E. Ziolkowska, J. Seredynska, A. Kamycka, W. Bal, T. Kubiatowski, T. Switaj, N. Kempa-Kaminska, E. Rutkowska, P. Rogala, G. Kamińska-Winciorek, R. Suwinski, J. Mackiewicz, P. Rutkowski
Journal: Annals of Oncology (2022)
1021P DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints
Authors: J.B. Kuon, M. Blasi, K. Kokowski, M. Faehling, W. Schuette, D.C.C. Christoph, M. Kimmich, W. Engel-Riedel, J. Fischer, M. Lehmann, M. Ulmer, P. Schuett, N. Moosmann, C. Meyer zum Bueschenfelde, F. Griesinger, M. Schneider, R. Behnisch, A. Stenzinger, P. Christopoulos, M. Thomas
Journal: Annals of Oncology (2022)
1154P Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer
Authors: S. Gendarme, S. Zebachi, R. Corre, L. Greillier, G. Justeau, O. Bylicki, C. Decroisette, J.B. Auliac, F. Guisier, M. Geier, C. Ricordel, M. Frelaut, E. Paillaud, C. Chouaid, F. Canouï-Poitrine
Journal: Annals of Oncology (2022)
1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations
Authors: S. Schmid, L.J. Zhan, M. Garcia, S. Cheng, K. Khan, M.T. Chowdhury, A. Sabouhanian, J. Herman, P. Walia, E. Strom, M.C. Brown, D. Patel, W. Xu, F.A. Shepherd, A. Sacher, N. Leighl, P. Bradbury, D. Shultz, G. Liu
Journal: Annals of Oncology (2022)
1271P A phase II study of high-flow nasal cannula as palliative care in advanced cancer patients
Authors: E. Takase, H. Akamatsu, S. Teraoka, K. Nakaguchi, M. Tanaka, T. Kaki, K. Furuta, K. Sato, E. Murakami, T. Sugimoto, R. Shibaki, D. Fujimoto, A. Hayata, N. Tokudome, Y. Ozawa, M. Nakanishi, Y. Koh, K. Kanai, T. Shimokawa, N. Yamamoto
Journal: Annals of Oncology (2022)
1078P Correlation between T cell immunity and EGFR-TKI treatment in patients harboring EGFR driver mutation
Authors: A. Mouri, K. Kaira, O. Yamaguchi, A. Shiono, Y. Miura, K. Hashimoto, F. Nishihara, H. Imai, K. Kobayashi, H. Kagamu
Journal: Annals of Oncology (2022)
1242P Thromboembolic events and their association with the overall survival in a large European cohort with gastroesophageal cancer
Authors: H.C. Puhr, M.A. Dieterle, F. Selimi, K. Oberreiter, C.C. Weirauch, L. Eischer, S. Eichinger, A.S.S. Berghoff, M. Preusser, A. Ilhan-Mutlu
Journal: Annals of Oncology (2022)
1081P DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients
Authors: M. Filetti, M. Occhipinti, A. Cirillo, F. Scirocchi, A. Ugolini, M. Petti, R. Giusti, P. Lombardi, A. Botticelli, G. Lo Russo, F.G.M. De Braud, P. Marchetti, M. Nuti, E. Ferretti, A. Rughetti, L. Farina
Journal: Annals of Oncology (2022)
1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy
Authors: A. Bronstein, R. Gervais, I. Monnet, C. Ricordel, L. Bigay-Game, M. Geier, C. Decroisette, C. Daniel, F. Guisier, A. Swalduz, A.C. Toffart, H. Doubre, J.M. Peloni, D. Arpin, H. Morel, R. Veillon, B. Clarisse, C. Chouaid, L. Greillier, O. Bylicki
Journal: Annals of Oncology (2022)
1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)
Authors: D.R. Spigel, P. Garrido Lopez, S. Cousin, P.K. Cheema, L.M. Rodríguez, M.C. Garassino, M. Kijewska, A. Majumdar, D.S. Theti, S. Roy-Ghanta, M. Ballas, M. Reck
Journal: Annals of Oncology (2022)
1251P CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)
Authors: S. Mukherjee, S. Lord, R. Harman, D. McIntosh, A. Ooms, M. Parkes, G. Radhakrishna, P.H. Shaw, M.A. Hawkins
Journal: Annals of Oncology (2022)
1184P Improving the tolerability of osimertinib by identifying its toxic limit
Authors: B.C. Agema, M.G.D. Veerman, D. Lanser, C.M.J. Steendam, T. Preijers, C. Van Der Leest, B. Koch, A-M.C. Dingemans, R.H. Mathijssen, S.L. Koolen
Journal: Annals of Oncology (2022)
1243P Influence of home nutritional therapy on body weight in patients with esophageal cancer after surgery: A prospective observational study
Authors: L. Dai, K-N. Chen, None Y. Wu, J. Ma, S. Guo, H. Tian, G. Xiao, W. Liu, M. He, C. Chen, X. Shi, Z. Wang, J. Liu, W. Guo, Y. Cui, T. Dai, X. Fu, W. Jiao
Journal: Annals of Oncology (2022)
1245P Outcomes and tolerability of neoadjuvant chemoradiation in elderly patients with oesophageal cancer: An Irish cancer centre retrospective analysis
Authors: R.A. Mclaughlin, M. Almeraikhi, H. Alkaabi, F. Bligh, C. Cluxton, D.J. McMahon, O.M. Fitzpatrick, M. Conroy, B.T. Hennessy, B. O'Neill, O.S. Breathnach, J. Naidoo, W.M. Grogan, A.G. Murphy, P.G. Morris
Journal: Annals of Oncology (2022)
1231P Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Authors: M. Jove, I. Brana, M. Oliva Bernal, A. Hernando-Calvo, C. Erasun Lecuona, J.D. Assaf Pastrana, M. Bazan Peregrino, A. Mato-Berciano, M.V. Maliandi, S. Torres-Manjon, J. Martinez de Villareal, F.X. Real, P.G. Nuciforo, R. Alemany, G. Capella, E. Blasi, C. Blasco, M. Cascallo Piqueras, R. Mesia Nin
Journal: Annals of Oncology (2022)
1132P Prevalence of the synonymous EGFR Q787Q variant in Mexican patients with non-small cell lung cancer
Authors: M. Ramos-Ramirez, N.Y. Hernandez-Pedro, M. Arroyo-Hernández, A. Aviles-Salas, L.A. Cabrera Miranda, K. Martinez-Perez, S. Monraz-Perez, O.G. Arrieta Rodriguez
Journal: Annals of Oncology (2022)
1273P Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center
Authors: A. Brunello, A. Galiano, S. Schiavon, I. Guglieri, D. Nucci, A. Pambuku, A. Dal Col, F. Bergamo, S. Finotto, M. Bolshinsky, S. Stragliotto, M.D. Rizzato, S. Lonardi, V. Zagonel
Journal: Annals of Oncology (2022)
1087P Predictive value of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) in patients (pts) with EGFR exon 20 insertion (ex20ins)-positive metastatic non-small cell lung cancer (mNSCLC) receiving mobocertinib therapy
Authors: P. Hofman, Z. Su, X. Tong, V. Bunn, S. Jin, S. Vincent
Journal: Annals of Oncology (2022)
1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116)
Authors: D.P. Modest, V. Heinemann, P. Schütt, S. Angermeier, M. Haberkorn, O. Waidmann, U. Graeven, K. Wille, V. Kunzmann, L. Henze, C. Constantin, M. De Wit, C. Denzlinger, A. Kurreck, A.H.S. Alig, A. Stahler, U. Pelzer, S. Stintzing, H. Oettle
Journal: Annals of Oncology (2022)
1350P Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations
Authors: S. van Waalwijk van Doorn-Khosrovani, L.J. Zeverijn, B.S. Geurts, G.F. de Wit, I.A.C. Spiekman, A. Pisters, A.M.G. Pasmooij, L. Timmers, H.P. Nygren, K.S. Rohrberg, K. Peltola, M.V.J. Mustonen, U.N. Lassen, A. Helland, H. Gelderblom, H.M.W. Verheul, K. Tasken, E.E. Voest
Journal: Annals of Oncology (2022)
1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy
Authors: G. Mellgard, Z. Chakrani, S. McCroskery, N. Saffran, N. Taylor, B. Liaw, M.D. Galsky, W. Oh, C-K. Tsao, V. Patel
Journal: Annals of Oncology (2022)
1299P PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial
Authors: J. Du, C. Lu, W. Kong, Y. Zhu, Q. Xin, H. Cheng, G. Li, M. Tang, J. Chen, Q. Li, A. Li, Q. Gu, Q. Xiaoping, S. Bao, L. Wang, Y. Qiu, B. Liu
Journal: Annals of Oncology (2022)
1099P Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients
Authors: F. Parisi, G. De Luca, G. Rossi, S. Coco, C. Dellepiane, E. Bennicelli, L. Zinoli, L. Zullo, A. Alama, M. Mosconi, M. Mora, A. Ballestrero, F. Montecucco, S. Marconi, P. Pronzato, L. Del Mastro, P. Nozza, A. Bellodi, M. Dono, C. Genova
Journal: Annals of Oncology (2022)
1228P Stage migration, changed treatment profile and survival impact in newly diagnosed oesophago-gastric cancer in Scotland during the COVID-19 pandemic: A national study
Authors: M. Baxter, K.S. Khan, L. Gall, C. Samuelson, L.R. Narramneni, M. Al-Zuabi, G. Bryce, H. Shareef, R. Petty, M. Forshaw
Journal: Annals of Oncology (2022)
1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
Authors: B.C. Cho, M-J. Ahn, T.M. Kim, C. Kim, B.Y. Shim, J-Y. Han, A.E. Drilon, H. Lena, J.E. Gomez, J.E. Gray, M. Awad, J. Perez, M. Navas, M. Kaul, S. Patel, B. Gao, H. Magnan, P. Rietschel
Journal: Annals of Oncology (2022)
1136P Relationship between caloric intakes and sensitivity to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients: The ELY-2 study
Authors: M. Tiako Meyo, G. Ulmann, P. Boudou Rouquette, J. Arrondeau, J.Q.Y. Chen, L. Hirsch, N. Neveux, C. Guidet, H. Lawand, M. Wislez, J. Alexandre, J-P. Durand, F. Goldwasser
Journal: Annals of Oncology (2022)
1326P Oncology under attack by predatory journals: A global survey
Authors: K. El Bairi, D. Trapani, S.J. Nidhamalddin, S. Zeb Khan, A.R. Chowdhury, C.G. Lengyel, S. Hussain, B. Habibe, A. Petrillo, N.E. Omar, S.C. Altuna, F.U. Seid, E. Elfaham, A. Seeber, F.S.R. Roitberg, A. Burguete, S. Elkefi, N. Hammad, O. Al Jarroudi, S. Afqir
Journal: Annals of Oncology (2022)
1256P Three courses of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective phase II clinical trial
Authors: G. Yang, X. Sun, H. Yang, G. Luo, Y. Zheng, M. Huang, Z. Wang, P. Cai, H. He, J. Xiang, M. Cai, J. Fu, Q. Liu, H. Yi, J. Zhong, Y. Huang, Q. Guo, X. Zhang
Journal: Annals of Oncology (2022)
1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations
Authors: M. Milella, G. Orsi, A. Palloni, L. Salvatore, L. Procaccio, S. Noventa, S. Bozzarelli, I. Garajova, E. Vasile, G. Giordano, M. Macchini, A. Cavaliere, M. Gaule, S. Lonardi, M.C. Di Marco, G. Tortora, I. Sperduti, M. Reni
Journal: Annals of Oncology (2022)
1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
Authors: K. Shitara, I. Ben-Aharon, C. Rojas, D.A. Acosta Eyzaguirre, A. Hubert, H. Araya Moya, D. Cohen, L-Y. Bai, F. Ghiringhelli, L. Wyrwicz, Y.Y. Janjigian, J. Tabernero, E. Van Cutsem, S. Qin, J. Xu, A. Wang, M.G. Miller, C-S. Shih, P. Bhagia, P.E. Yanez Weber
Journal: Annals of Oncology (2022)
1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay
Authors: C.Y.K. Fong, S. Iyer, L. Potts, C. Peckitt, S. Cromarty, C. Saffery, S. Kidd, T. Rana, L. Ausec, A. Gregorc, D. Pointing, M. Gombert, K. von Loga, L. Benjamin, N. Starling, T.S. Waddell, R. Petty, M. Uhlik, I. Chau, D. Cunningham
Journal: Annals of Oncology (2022)
1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
Authors: G. Gravis Mescam, X. Maldonado, G. Roubaud, R.S. McDermott, A. Flechon, B. Tombal, S. Supiot, D.R. Berthold, R. Philippe, G. Kacso, F. Calabrò, J.F. Berdah, A. Hasbini, M. Silva, A. Thiery-Vuillemin, A. Rodriguez-Vida, J.A. McCaffrey, H. Ribault, S. Foulon, K. Fizazi
Journal: Annals of Oncology (2022)
1240P Activation status of CD8+ T and Treg cells in the tumor microenvironment potentially predicts the clinical efficacy of nivolumab in advanced esophageal squamous cell carcinoma
Authors: H. Mikuni, G. Watanabe, S. Kumagai, S. Yamamoto, R. Sawada, K. Yokoyama, Y. Honma, S. Sekine, T. Kashihara, K. Ishiyama, J. Oguma, H. Igaki, M. Saruta, H. Daiko, S. Koyama, H. Nishikawa, K. Kato
Journal: Annals of Oncology (2022)
1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6
Authors: Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, A. Gnanasakthy, A. Jamotte, I. Majer, Y-K. Kang
Journal: Annals of Oncology (2022)
1116P United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review
Authors: M. Julve, O. Kennedy, C. Lindsay, R. Walters-Davies, M.R. Button, N. Steele, A. McGeogh, A. Georgiou, B. Goranov, D. Farrugia, L. Gorf, M. Remer, R. Shah, S. Baijal, S. Gennatas, T. Geldart, E. Daniels, L. Watts, A. Greystoke, T. Newsom-Davis
Journal: Annals of Oncology (2022)
1162P Tissue and liquid biopsy utilization in advanced NSCLC in a large community US practice
Authors: L.N. Gordan, M. Diaz, A. Patel, M. Fink, D. Wenk, A. Roos, J. Jiang, J. Tam, P. Sathyan, P. Febbo
Journal: Annals of Oncology (2022)
1300P Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer
Authors: A. Singhi, T. Chen, R.W. Madison, N. Bhardwaj, D.X. Jin, Z. Fleischmann, J. Newberg, J. Moore, G.M. Frampton, P. Hegde, D.A. Fabrizio, J. He, A.B. Schrock, E. Ebot, E.S. Sokol
Journal: Annals of Oncology (2022)
1235P Analytical performance of PD-L1 IHC 28-8 pharmDx in gastric, gastroesophageal junction (GEJ), and esophageal carcinoma evaluated using combined positive score (CPS)
Authors: T. Chan, B. Neill, A. Murga, K.M. Sojka, S. Thakrar, Q. Nguyen, C. Felten, J. Blaustein, D. Falconer, T. Marquez, K. Wakamiya, S.C. Hsu, D. Houston, N. Hertle, S. Tabuena-Frolli, M. Borgert, S. Smith, E. Oroudjev
Journal: Annals of Oncology (2022)
1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
Authors: F. Keane, W. Park, A. Varghese, F. Balogun, K. Yu, I. El Dika, D. Khalil, D.P. Kelsen, D. Reidy-Lagunes, G.Y. Ku, N. Raj, J.F. Chou, M. Capanu, N. Schultz, R. Yaeger, E. O'Reilly
Journal: Annals of Oncology (2022)
1103P Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: A real-world setting
Authors: Y. Sato, H. Sumikawa, R. Shibaki, T. Morimoto, Y. Sakata, Y. Oya, M. Tamiya, H. Suzuki, H. Matsumoto, T. Kijima, K. Hashimoto, H. Kobe, A. Hino, M. Inaba, Y. Tsukita, H. Ikeda, D. Arai, H. Maruyama, S. Sakata, D. Fujimoto
Journal: Annals of Oncology (2022)
1216P Prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma under HER2 blockade and immune checkpoint therapy
Authors: L. Paschold, A. Stein, S. Henkes, J. Tintelnot, E. Goekkurt, D. Simnica, C. Schultheiß, E. Willscher, M. Bauer, C. Wickenhauser, P.C. Thuss-Patience, S. Lorenzen, J. Riera Knorrenschild, S. Kubicka, A. Reinacher-Schick, M. Sinn, W. Hiegl, A. Hinke, S. Hegewisch-Becker, M. Binder
Journal: Annals of Oncology (2022)
1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC
Authors: E. Auclin, P. Du Rusquec, V. Albarran, F. Aboubakar, H. Gerber, N. Epaillard, G. Recondo, H. Berthou, E. Fabre-Guillevin, J.C. Laguna Montes, J.B. Blaquier, B.E. Jimenez Munarriz, M. Tagliamento, G. Sacco, J.N. Minatta, N. Girard, M.T. Moran Bueno, R. López Castro, B. Besse, L. Mezquita
Journal: Annals of Oncology (2022)
1194TiP AdvanTIG-205: Phase II trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
Authors: B. Zhu, T.M. Kim, S.A. Patel, S. Parakh, J. Tang, H. Wu, N. Girard
Journal: Annals of Oncology (2022)
1117P Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy
Authors: N. Girard, S. Popat, N. Rahhali, B. Rodrigues, C.A. Schioppa, C. Pick-Lauer, A. Adamczyk, J. Sermon, J. Diels, J. Penton, M. Thomas
Journal: Annals of Oncology (2022)
1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma
Authors: K. Muro, K. Kato, K. Chin, K. Nishino, M. Satouchi, Y. Watanabe, H. Kawakami, T. Tsushima, H. Hirai, M. Chisamore, T. Kojima
Journal: Annals of Oncology (2022)
1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
Authors: A. Passaro, G. Lo Russo, F. Passiglia, M. D'Arcangelo, A. Sbrana, M. Russano, L. Bonanno, R. Giusti, G. Metro, F. Bertolini, S. Grisanti, A. Carta, F.L. Cecere, M. Montrone, G. Massa, I. Attili, F. de Marinis
Journal: Annals of Oncology (2022)
1254P Updated report of a phase I study of TST001, a humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer
Authors: L. Shen, J. Gong, N. Li, W. Guo, J. Zhang, Q. Fan, T. Liu, Z. Xia, None Y. Shen, J. Wang, L. Lu, C. Qi, J. Yao, X. Qian, M. Shi
Journal: Annals of Oncology (2022)
1084P Predicting KRAS G12C subtype from non-small cell lung cancer H&amp;E slides using deep learning
Authors: I. Soubeyran, R. Dubois, M. Jacquemin, K. Courtet, None Y. Laizet, C. Lucchesi, B. Allard, A. Rousset, A. Jaeger, J. Moreira, E. Khalifa, B. Bonhomme, A. Italiano
Journal: Annals of Oncology (2022)
1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)
Authors: L. Corke, M. García Pardo de Santayana, K. Meteleva, F.A. Shepherd, P. Bradbury, L. Eng, S. Kuang, M. Cabanero, P. Rogalla, G. Liu, M-S. Tsao, T.J. Pugh, B. Wang, P. Ohashi, N. Leighl, A. Sacher
Journal: Annals of Oncology (2022)
1239P Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma
Authors: L.G. Aoude, V.F. Bonazzi, S. Brosda, B. Wong, H. Moradi, J. Lonie, J. Bradford, C. Bloxham, V.G. Atkinson, P. Law, G. Lampe, M. Smithers, N. Waddell, V. Vegh, K. Miles, A.P. Barbour
Journal: Annals of Oncology (2022)